Fragile x mental retardation protein: From autism to neurodegenerative disease

Frontiers in Cellular Neuroscience

Volumn 9, Issue FEB, 2015, Pages 7-

  Wang, Hansen ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alzheimer disease; Autism; FMRP; Fragile X syndrome; Neurodegeneration; Synaptic plasticity; Tau; amyloid

Indexed keywords

ACTIVITY REGULATED CYTOSKELETON ASSOCIATED PROTEIN; AMYLOID PRECURSOR PROTEIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; EPHRIN RECEPTOR B2; FRAGILE X MENTAL RETARDATION PROTEIN; GLUTAMATE RECEPTOR; INITIATION FACTOR 4E; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; P21 ACTIVATED KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; POSTSYNAPTIC DENSITY PROTEIN 95; PROTEIN TYROSINE PHOSPHATASE; RAC1 PROTEIN; RNA BINDING PROTEIN; S6 KINASE; SURVIVAL MOTOR NEURON PROTEIN 1; TAR DNA BINDING PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; AUTISM; DEGENERATIVE DISEASE; ENZYME ACTIVITY; FRAGILE X SYNDROME; GENE EXPRESSION; HUMAN; INTERNALIZATION; NONHUMAN; PROTEIN BINDING; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; TRANSLATION REGULATION;

EID: 84923257346     PISSN: 16625102     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncel.2015.00043     Document Type: Article

References (94)

1. Abekhoukh, S., and Bardoni, B. (2014). CYFIP family proteins between autism and intellectual disability: links with Fragile X syndrome. Front. Cell. Neurosci. 8:81. doi: 10.3389/fncel.2014.00081.
2. Auerbach, B. D., Osterweil, E. K., and Bear, M. F. (2011). Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature 480, 63-68. doi: 10.1038/nature10658.
3. Bamburg, J. R., and Bloom, G. S. (2009). Cytoskeletal pathologies of Alzheimer disease. Cell Motil. Cytoskeleton 66, 635-649. doi: 10.1002/cm.20388.
4. Banerjee, S., Riordan, M., and Bhat, M. A. (2014). Genetic aspects of autism spectrum disorders: insights from animal models. Front. Cell. Neurosci. 8:58. doi: 10.3389/fncel.2014.00058.
5. Bassell, G. J., and Warren, S. T. (2008). Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron 60, 201-214. doi: 10.1016/j.neuron.2008.10.004.
6. Belmonte, M. K., and Bourgeron, T. (2006). Fragile X syndrome and autism at the intersection of genetic and neural networks. Nat Neurosci 9, 1221-1225. doi: 10.1038/nn1765.
7. Benilova, I., Karran, E., and De Strooper, B. (2012). The toxic Abeta oligomer and Alzheimer’s disease: an emperor in need of clothes. Nat. Neurosci. 15, 349-357. doi: 10.1038/nn.3028.
8. Bhakar, A. L., Dolen, G., and Bear, M. F. (2012). The pathophysiology of fragile X. (and what it teaches us about synapses). Annu. Rev. Neurosci. 35, 417-443. doi: 10.1146/annurev-neuro-060909153138.
9. Bloom, G. S. (2014). Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 71, 505-508. doi: 10.1001/jamaneu-rol.2013.5847.
10. Boehm, J. (2013). A ‘danse macabre’: tau and Fyn in STEP with amyloid beta to facilitate induction of synaptic depression and excitotoxicity. Eur. J. Neurosci. 37, 1925-1930. doi: 10.1111/ejn.12251.
11. Braithwaite, S. P., Stock, J. B., Lombroso, P. J., and Nairn, A. C. (2012). Protein phosphatases and Alzheimer’s disease. Prog. Mol. Biol. Transl. Sci. 106, 343-379. doi: 10.1016/B978-0-12-396456-4.00012-2.
12. Budimirovic, D. B., and Kaufmann, W. E. (2011). What can we learn about autism from studying fragile X syndrome? Dev. Neurosci. 33, 379-394. doi: 10.1159/000330213.
13. Caccamo, A., De Pinto, V., Messina, A., Branca, C., and Oddo, S. (2014). Genetic reduction of mammalian target of rapamycin ameliorates Alzheimer’s disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature. J. Neurosci. 34, 7988-7998. doi: 10.1523/JNEUROSCI.0777-14.2014.
14. Chang, P. K., Verbich, D., and McKinney, R. A. (2012). AMPA receptors as drug targets in neurological disease-advantages, caveats, and future outlook. Eur. J. Neurosci. 35, 1908-1916. doi: 10.1111/j.1460-9568.2012.08165.x.
15. Chen, X., Nelson, C. D., Li, X., Winters, C. A., Azzam, R., Sousa, A. A., et al. (2011). PSD-95 is required to sustain the molecular organization of the postsynaptic density. J. Neurosci. 31, 6329-6338. doi: 10.1523/JNEUROSCI.5968-10.2011.
16. Chowdhury, S., Shepherd, J. D., Okuno, H., Lyford, G., Petralia, R. S., Plath, N., et al. (2006). Arc/Arg3.1 interacts with the endocytic machinery to regulate AMPA receptor trafficking. Neuron 52, 445-459. doi: 10.1016/j.neuron.2006.08.033.
17. Cisse, M., and Checler, F. (2014). Eph receptors: new players in Alzheimer’s disease pathogenesis. Neurobiol. Dis. 73C, 137-149. doi: 10.1016/j.nbd.2014.08.028.
18. Cisse, M., Halabisky, B., Harris, J., Devidze, N., Dubal, D. B., Sun, B., et al. (2011). Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature 469, 47-52. doi: 10.1038/nature09635.
19. Cook, D., Nuro, E., and Murai, K. K. (2014). Increasing our understanding of human cognition through the study of Fragile X Syndrome. Dev. Neurobiol. 74, 147-177. doi: 10.1002/dneu.22096.
20. Darnell, J. C., and Klann, E. (2013). The translation of translational control by FMRP: therapeutic targets for FXS. Nat. Neurosci. 16, 1530-1536. doi:10.1038/nn.3379.
21. Feld, M., Krawczyk, M. C., Sol Fustinana, M., Blake, M. G., Baratti, C. M., Romano, A., et al. (2014). Decrease of ERK/MAPK overactivation in prefrontal cortex reverses early emory deficit in a mouse model of Alzheimer’s disease. J. Alzheimers Dis. 40, 69-82. doi: 10.3233/JAD-131076.
22. Giacobini, E., and Gold, G. (2013). Alzheimer disease therapy-moving from amyloid-beta to tau. Nat. Rev. Neurol. 9, 677-686. doi: 10.1038/nrneurol.2013.223.
23. Goebel-Goody, S. M., Wilson-Wallis, E. D., Royston, S., Tagliatela, S. M., Naegele, J. R., and Lombroso, P. J. (2012). Genetic manipulation of STEP reverses behavioral abnormalities in a fragile X syndrome mouse model. Genes Brain Behav. 11, 586-600. doi:10.1111/j.1601-183X.2012.00781.x.
24. Gotz, J., Ittner, A., and Ittner, L. M. (2012). Tautargeted treatment strategies in Alzheimer’s disease. Br. J. Pharmacol. 165, 1246-1259. doi: 10.1111/j.1476-5381.2011.01713.x.
25. Griffin, R. J., Moloney, A., Kelliher, M., Johnston, J. A., Ravid, R., Dockery, P., et al. (2005). Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer’s disease pathology. J. Neurochem. 93, 105-117. doi: 10.1111/j.1471-4159.2004.02949.x.
26. Gross, C., and Bassell, G. J. (2014). Neuron-specific regulation of class I PI3K catalytic subunits and their dysfunction in brain disorders. Front. Mol. Neurosci. 7:12. doi: 10.3389/fnmol.2014.00012.
27. Guo, W., Murthy, A. C., Zhang, L., Johnson, E. B., Schaller, E. G., Allan, A. M., et al. (2012). Inhibition of GSK3beta improves hippocampusdependent learning and rescues neurogenesis in a mouse model of fragile X syndrome. Hum. Mol. Genet. 21, 681-691. doi: 10.1093/hmg/ddr501.
28. Hamilton, A., Esseltine, J. L., DeVries, R. A., Cregan, S. P., and Ferguson, S. S. (2014). Metabotropic glutamate receptor 5 knockout reduces cognitive impairment and pathogenesis in a mouse model of Alzheimer’s disease. Mol. Brain 7:40. doi: 10.1186/1756-6606-7-40.
29. Himmelstein, D. S., Ward, S. M., Lancia, J. K., Patterson, K. R., and Binder, L. I. (2012). Tau as a therapeutic target in neurodegenerative disease. Pharmacol. Ther. 136, 8-22. doi: 10.1016/j.pharmthera.2012.07.001.
30. Holtzman, D. M., Mandelkow, E., and Selkoe, D. J. (2012). Alzheimer disease in 2020. Cold Spring Harb. Perspect. Med. 2:a011585. doi: 10.1101/csh-perspect.a011585.
31. Karran, E., Mercken, M., and de Strooper, B. (2011). The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics. Nat. Rev. Drug Discov. 10, 698-712. doi: 10.1038/nrd3505.
32. Klein, W. L. (2013). Synaptotoxic amyloid-beta oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer’s disease? J. Alzheimers Dis. 33(Suppl. 1), 49-65. doi: 10.3233/JAD-2012-129039.
33. Klyubin, I., Cullen, W. K., Hu, N. W., and Rowan, M. J. (2012). Alzheimer’s disease Abeta assemblies mediating rapid disruption of synaptic plasticity and memory. Mol. Brain 5:25. doi: 10.1186/17566606-5-25.
34. Lacor, P. N., Buniel, M. C., Chang, L., Fernandez, S. J., Gong, Y., Viola, K. L., et al. (2004). Synaptic targeting by Alzheimer’s-related amyloid beta oligomers. J. Neurosci. 24, 10191-10200. doi: 10.1523/JNEUROSCI.3432-04.2004.
35. Lafay-Chebassier, C., Paccalin, M., Page, G., Barc-Pain, S., Perault-Pochat, M. C., Gil, R., et al. (2005). MTOR/p70S6k signalling alteration by Abeta exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer’s disease. J. Neurochem. 94, 215-225. doi: 10.1111/j.14714159.2005.03187.x.
36. Larson, M. E., and Lesne, S. E. (2012). Soluble Abeta oligomer production and toxicity. J. Neurochem. 120 (Suppl. 1), 125-139. doi: 10.1111/j.1471-4159.2011.07478.x.
37. Larson, M., Sherman, M. A., Amar, F., Nuvolone, M., Schneider, J. A., Bennett, D. A., et al. (2012). The complex PrP(c)-Fyn couples human oligomeric Abeta with pathological tau changes in Alzheimer’s disease. J. Neurosci. 32, 16857a-16871a. doi: 10.1523/JNEUROSCI.1858-12.2012.
38. Lauren, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., and Strittmatter, S. M. (2009). Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457, 1128-1132. doi: 10.1038/nature07761.
39. Lee, E. K., Kim, H. H., Kuwano, Y., Abdelmohsen, K., Srikantan, S., Subaran, S. S., et al. (2010). HnRNP C promotes APP translation by competing with FMRP for APP mRNA recruitment to P bodies. Nat. Struct. Mol. Biol. 17, 732-739. doi: 10.1038/nsmb.1815.
40. Lisman, J., Yasuda, R., and Raghavachari, S. (2012). Mechanisms of CaMKII action in long-term potentiation. Nat. Rev. Neurosci. 13, 169-182. doi: 10.1038/nrn3192..
41. Llorens-Martin, M., Jurado, J., Hernandez, F., and Avila, J. (2014). GSK-3beta, a pivotal kinase in Alzheimer disease. Front. Mol. Neurosci. 7:46. doi: 10.3389/fnmol.2014.00046.
42. Ma, Q. L., Yang, F., Calon, F., Ubeda, O. J., Hansen, J. E., Weisbart, R. H., et al. (2008). p21-activated kinase-aberrant activation and translocation in Alzheimer disease pathogenesis. J. Biol. Chem. 283, 14132-14143. doi: 10.1074/jbc.M708034200.
43. Ma, Q. L., Yang, F., Frautschy, S. A., and Cole, G. M. (2012). PAK in Alzheimer disease, Huntington disease and X-linked mental retardation. Cell. Logist. 2, 117-125. doi: 10.4161/cl.21602.
44. Malinow, R. (2012). New developments on the role of NMDA receptors in Alzheimer’s disease. Curr. Opin. Neurobiol. 22, 559-563. doi: 10.1016/j.conb.2011.09.001.
45. Maloney, M. T., and Bamburg, J. R. (2007). Cofilinmediated neurodegeneration in Alzheimer’s disease and other amyloidopathies. Mol. Neurobiol. 35, 21-44. doi: 10.1007/BF02700622.
46. Malter, J. S., Ray, B. C., Westmark, P. R., and Westmark, C. J. (2010). Fragile X Syndrome and Alzheimer’s disease: another story about APP and beta-amyloid. Curr. Alzheimer Res. 7, 200-206. doi: 10.2174/156720510791050957.
47. Martin, L., Latypova, X., Wilson, C. M., Magnaudeix, A., Perrin, M. L., and Terro, F. (2013a). Tau protein phosphatases in Alzheimer’s disease: the leading role of PP2A. Ageing Res. Rev. 12, 39-49. doi: 10.1016/j.arr.2012.06.008.
48. Martin, L., Latypova, X., Wilson, C. M., Magnaudeix, A., Perrin, M. L., Yardin, C., et al. (2013b). Tau protein kinases: involvement in Alzheimer’s disease. Ageing Res. Rev. 12, 289-309. doi: 10.1016/j.arr.2012.06.003.
49. Masters, C. L., and Selkoe, D. J. (2012). Biochemistry of amyloid beta-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2:a006262. doi: 10.1101/cshperspect.a006262.
50. Medina, M., and Avila, J. (2014). New perspectives on the role of tau in Alzheimer’s disease. Implications for therapy. Biochem. Pharmacol. 88, 540-547. doi: 10.1016/j.bcp.2014.01.013.
51. Moriguchi, S. (2011). Pharmacological study on Alzheimer’s drugs targeting calcium/calmodulindependent protein kinase II. J. Pharmacol. Sci. 117, 6-11. doi: 10.1254/jphs.11R06CP.
52. Mucke, L., and Selkoe, D. J. (2012). Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. Cold Spring Harb. Perspect. Med. 2:a006338. doi: 10.1101/cshperspect.a006338.
53. Myrick, L. K., Deng, P. Y., Hashimoto, H., Oh, Y. M, Cho, Y., Poidevin, M. J., et al. (2015). Independent role for presynaptic FMRP revealed by an FMR1 missense mutation associated with intellectual disability and seizures. Proc. Natl. Acad. Sci. U.S.A. 112, 949-956. doi: 10.1073/pnas.1423094112.
54. Nygaard, H. B., van Dyck, C. H., and Strittmatter, S. M. (2014). Fyn kinase inhibition as a novel therapy for Alzheimer’s disease. Alzheimers Res. Ther. 6, 8. doi: 10.1186/alzrt238.
55. Osterweil, E. K., Chuang, S. C., Chubykin, A. A., Sidorov, M., Bianchi, R., Wong, R. K., et al. (2013). Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. Neuron 77, 243-250. doi: 10.1016/j.neuron.2012.01.034.
56. Overk, C. R., and Masliah, E. (2014). Pathogenesis of synaptic degeneration in Alzheimer’s disease and Lewy body disease. Biochem. Pharmacol. 88, 508-516. doi: 10.1016/j.bcp.2014.01.015.
57. Pasciuto, E., and Bagni, C. (2014a). SnapShot: FMRP interacting proteins. Cell 159, 218-e211. doi: 10.1016/j.cell.2014.08.036.
58. Pasciuto, E., and Bagni, C. (2014b). SnapShot: FMRP mRNA targets and diseases. Cell 158, 1446-e1441. doi: 10.1016/j.cell.2014.08.035.
59. Paula-Lima, A. C., Brito-Moreira, J., and Ferreira, S. T. (2013). Deregulation of excitatory neurotransmission underlying synapse failure in Alzheimer’s disease. J. Neurochem. 126, 191-202. doi: 10.1111/jnc.12304.
60. Penzes, P., and Vanleeuwen, J. E. (2011). Impaired regulation of synaptic actin cytoskeleton in Alzheimer’s disease. Brain Res. Rev. 67, 184-192. doi: 10.1016/j.brainresrev.2011.01.003.
61. Pozueta, J., Lefort, R., and Shelanski, M. L. (2013). Synaptic changes in Alzheimer’s disease and its models. Neuroscience 251, 51-65. doi: 10.1016/j.neuroscience.2012.05.050.
62. Roberson, E. D., Halabisky, B., Yoo, J. W., Yao, J., Chin, J., Yan, F., et al. (2011). Amyloid-beta/Fyninduced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer’s disease. J. Neurosci. 31, 700-711. doi: 10.1523/JNEUROSCI.4152-10.2011.
63. Ronesi, J. A., and Huber, K. M. (2008). Metabotropic glutamate receptors and fragile x mental retardation protein: partners in translational regulation at the synapse. Sci. Signal. 1:e6. doi: 10.1126/stke.15pe6.
64. Santini, E., and Klann, E. (2014). Reciprocal signaling between translational control pathways and synaptic proteins in autism spectrum disorders. Sci. Signal. 7:e10. doi: 10.1126/scisignal.2005832.
65. Santoro, M. R., Bray, S. M., and Warren, S. T. (2012). Molecular mechanisms of fragile X syndrome: a twenty-year perspective. Annu. Rev. Pathol. 7, 219-245. doi: 10.1146/annurev-pathol011811-132457.
66. Selkoe, D. J. (2011). Alzheimer’s disease. Cold Spring Harb. Perspect. Biol. 3:a004457. doi: 10.1101/cshperspect.a004457.
67. Sheng, M., Sabatini, B. L., and Sudhof, T. C. (2012). Synapses and Alzheimer’s disease. Cold Spring Harb. Perspect. Biol. 4:a005777. doi: 10.1101/csh-perspect.a005777.
68. Sidorov, M. S., Auerbach, B. D., and Bear, M. F. (2013). Fragile X mental retardation protein and synaptic plasticity. Mol. Brain 6:15. doi: 10.1186/1756-6606-6-15.
69. Sokol, D. K., Maloney, B., Long, J. M., Ray, B., and Lahiri, D. K. (2011). Autism, Alzheimer disease, and fragile X: APP, FMRP, and mGluR5 are molecular links. Neurology 76, 1344-1352. doi: 10.1212/WNL.0b013e3182166dc7.
70. Sontag, J. M., and Sontag, E. (2014). Protein phosphatase 2A dysfunction in Alzheimer’s disease. Front. Mol. Neurosci. 7:16. doi: 10.3389/fnmol.2014.00016.
71. Suhl, J. A., Chopra, P., Anderson, B. R., Bassell, G. J., and Warren, S. T. (2014). Analysis of FMRP mRNA target datasets reveals highly associated mRNAs mediated by G-quadruplex structures formed via clustered WGGA sequences. Hum. Mol. Genet. 23, 5479-5491. doi: 10.1093/hmg/ddu272.
72. Tu, S., Okamoto, S., Lipton, S. A., and Xu, H. (2014). Oligomeric Abeta-induced synaptic dysfunction in Alzheimer’s disease. Mol. Neurodegener. 9:48. doi: 10.1186/1750-1326-9-48.
73. Ubhi, K., and Masliah, E. (2013). Alzheimer’s disease: recent advances and future perspectives. J. Alzheimers Dis. 33(Suppl. 1), S185-S194. doi: 10.3233/JAD-2012-129028..
74. Um, J. W., Kaufman, A. C., Kostylev, M., Heiss, J. K., Stagi, M., Takahashi, H., et al. (2013). Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer abeta oligomer bound to cellular prion protein. Neuron 79, 887-902. doi: 10.1016/j.neuron.2013.06.036.
75. Um, J. W., Nygaard, H. B., Heiss, J. K., Kostylev, M. A., Stagi, M., Vortmeyer, A., et al. (2012). Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat. Neurosci. 15, 1227-1235. doi: 10.1038/nn.3178.
76. Vossel, K. A., Zhang, K., Brodbeck, J., Daub, A. C., Sharma, P., Finkbeiner, S., et al. (2010). Tau reduction prevents Abeta-induced defects in axonal transport. Science 330, 198. doi: 10.1126/science.1194653.
77. Wang, H. (2014). Lipid rafts: a signaling platform linking cholesterol metabolism to synaptic deficits in autism spectrum disorders. Front. Behav. Neurosci. 8:104. doi: 10.3389/fnbeh.2014.00104.
78. Wang, H., and Doering, L. C. (2013). Reversing autism by targeting downstream mTOR signaling. Front. Cell. Neurosci. 7:28. doi: 10.3389/fncel.2013.00028.
79. Wang, H., Kim, S. S., and Zhuo, M. (2010). Roles of fragile X mental retardation protein in dopaminergic stimulation-induced synapse-associated protein synthesis and subsequent alpha-amino3-hydroxyl-5-methyl-4-isoxazole-4-propionate. (AMPA). receptor internalization. J. Biol. Chem. 285, 21888-21901. doi: 10.1074/jbc.M110.116293.
80. Wang, H., Ren, C. H., Gunawardana, C. G., and Schmitt-Ulms, G. (2013). Overcoming barriers and thresholds signaling of oligomeric Abeta through the prion protein to Fyn. Mol. Neurodegener. 8:24. doi: 10.1186/1750-1326-8-24.
81. Wang, H., Wu, L. J., Kim, S. S., Lee, F. J., Gong, B., Toyoda, H., et al. (2008b). FMRP acts as a key messenger for dopamine modulation in the forebrain. Neuron 59, 634-647. doi: 10.1016/j.neuron.2008.06.027.
82. Wang, H., Wu, L. J., Zhang, F., and Zhuo, M. (2008a). Roles of calcium-stimulated adenylyl cyclase and calmodulin-dependent protein kinase IV in the regulation of FMRP by group I metabotropic glutamate receptors. J. Neurosci. 28, 4385-4397. doi: 10.1523/JNEUROSCI.0646-08.2008.
83. Wang, H., and Zhuo, M. (2012). Group I metabotropic glutamate receptor-mediated gene transcription and implications for synaptic plasticity and diseases. Front. Pharmacol. 3:189. doi: 10.3389/fphar.2012.00189.
84. Wang, J. Z., Grundke-Iqbal, I., and Iqbal, K. (2007). Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur. J. Neurosci. 25, 59-68. doi: 10.1111/j.1460-9568.2006.05226.x.
85. Wang, T., Bray, S. M., and Warren, S. T. (2012). New perspectives on the biology of fragile X syndrome. Curr. Opin. Genet. Dev. 22, 256-263. doi: 10.1016/j.gde.2012.02.002.
86. Waung, M. W., Pfeiffer, B. E., Nosyreva, E. D., Ronesi, J. A., and Huber, K. M. (2008). Rapid translation of Arc/Arg3.1 selectively mediates mGluR-dependent LTD through persistent increases in AMPAR endocytosis rate. Neuron 59, 84-97. doi: 10.1016/j.neuron.2008.05.014.
87. Westmark, C. J. (2013). What’s hAPPening at synapses? The role of amyloid beta-protein precursor and beta-amyloid in neurological disorders. Mol. Psychiatry 18, 425-434. doi: 10.1038/mp.2012.122.
88. Westmark, C. J., and Malter, J. S. (2007). FMRP mediates mGluR5-dependent translation of amyloid precursor protein. PLoS Biol. 5:e52. doi: 10.1371/journal.pbio.0050052.
89. Westmark, C. J., Westmark, P. R., O’Riordan, K. J., Ray, B. C., Hervey, C. M., Salamat, M. S., et al. (2011). Reversal of fragile X phenotypes by manipulation of AbetaPP/Abeta levels in Fmr1KO mice. PLoS ONE 6:e26549. doi: 10.1371/journal.pone.0026549.
90. Won, H., Lee, H. R., Gee, H. Y., Mah, W., Kim, J. I., Lee, J., et al. (2012). Autistic-like social behavior in Shank2-mutant mice improved by restoring NMDA receptor function. Nature 486, 261-265. doi: 10.1038/nature11208.
91. Zempel, H., and Mandelkow, E. (2014). Lost after translation: missorting of Tau protein and consequences for Alzheimer disease. Trends Neurosci. 37, 721-732. doi: 10.1016/j.tins.2014.08.004.
92. Zhang, Y., Kurup, P., Xu, J., Carty, N., Fernandez, S. M., Nygaard, H. B., et al. (2010). Genetic reduction of striatal-enriched tyrosine phosphatase. (STEP). reverses cognitive and cellular deficits in an Alzheimer’s disease mouse model. Proc. Natl. Acad. Sci. U.S.A. 107, 19014-19019. doi: 10.1073/pnas.1013543107.
93. Zhang, Y., Venkitaramani, D. V., Gladding, C. M., Kurup, P., Molnar, E., Collingridge, G. L., et al. (2008). The tyrosine phosphatase STEP mediates AMPA receptor endocytosis after metabotropic glutamate receptor stimulation. J. Neurosci. 28, 10561-10566. doi: 10.1523/JNEUROSCI.2666-08.2008.
94. Zoghbi, H. Y., and Bear, M. F. (2012). Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities. ColdSpringHarb.Perspect. Biol. 4:a009886. doi:10.1101/cshperspect.a009886.